Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry.

Scheidweiler KB, Barnes AJ.

Methods Mol Biol. 2019;1872:11-22. doi: 10.1007/978-1-4939-8823-5_2.

PMID:
30350275
2.

Pharmacodynamic Effects, Pharmacokinetics, and Metabolism of the Synthetic Cannabinoid AM-2201 in Male Rats.

Carlier J, Wohlfarth A, Salmeron BD, Scheidweiler KB, Huestis MA, Baumann MH.

J Pharmacol Exp Ther. 2018 Dec;367(3):543-550. doi: 10.1124/jpet.118.250530. Epub 2018 Sep 28.

3.

Optimization of recombinant β-glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry.

Sempio C, Scheidweiler KB, Barnes AJ, Huestis MA.

Drug Test Anal. 2018 Mar;10(3):518-529. doi: 10.1002/dta.2230. Epub 2017 Aug 16.

PMID:
28815938
4.

Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry.

Carlier J, Diao X, Scheidweiler KB, Huestis MA.

Clin Chem. 2017 May;63(5):1008-1021. doi: 10.1373/clinchem.2016.267575. Epub 2017 Mar 16.

5.

Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay.

Lee MR, Scheidweiler KB, Diao XX, Akhlaghi F, Cummins A, Huestis MA, Leggio L, Averbeck BB.

Mol Psychiatry. 2018 Jan;23(1):115-122. doi: 10.1038/mp.2017.27. Epub 2017 Mar 14.

6.

In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201).

Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler KB, Huestis MA.

Forensic Toxicol. 2017 Jan;35(1):20-32. doi: 10.1007/s11419-016-0326-9. Epub 2016 Jul 6.

7.

Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration.

Newmeyer MN, Swortwood MJ, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA.

Clin Chem. 2017 Mar;63(3):647-662. doi: 10.1373/clinchem.2016.265371. Epub 2017 Feb 10.

8.
9.

Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration.

Swortwood MJ, Newmeyer MN, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA.

Drug Test Anal. 2017 Jun;9(6):905-915. doi: 10.1002/dta.2092. Epub 2016 Oct 13.

10.

Maternal Buprenorphine Maintenance and Lactation.

Jansson LM, Spencer N, McConnell K, Velez M, Tuten M, Harrow CA, Jones HE, Swortwood MJ, Barnes AJ, Scheidweiler KB, Huestis MA.

J Hum Lact. 2016 Nov;32(4):675-681. doi: 10.1177/0890334416663198. Epub 2016 Sep 26.

PMID:
27563013
11.

Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes.

Diao X, Scheidweiler KB, Wohlfarth A, Zhu M, Pang S, Huestis MA.

Forensic Toxicol. 2016;34:256-267. Epub 2016 Mar 28.

12.

Long-term stability of cannabinoids in oral fluid after controlled cannabis administration.

Scheidweiler KB, Andersson M, Swortwood MJ, Sempio C, Huestis MA.

Drug Test Anal. 2017 Jan;9(1):143-147. doi: 10.1002/dta.2056. Epub 2016 Sep 13.

13.

Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips.

Andersson M, Scheidweiler KB, Sempio C, Barnes AJ, Huestis MA.

Anal Bioanal Chem. 2016 Sep;408(23):6461-71. doi: 10.1007/s00216-016-9765-8. Epub 2016 Jul 15.

14.

Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry.

Scheidweiler KB, Newmeyer MN, Barnes AJ, Huestis MA.

J Chromatogr A. 2016 Jul 1;1453:34-42. doi: 10.1016/j.chroma.2016.05.024. Epub 2016 May 7.

15.

Quantification of [1-(5-fluoropentyl)-1H-indol-3-yl](naphthalene-1-yl)methanone (AM-2201) and 13 metabolites in human and rat plasma by liquid chromatography-tandem mass spectrometry.

Carlier J, Scheidweiler KB, Wohlfarth A, Salmeron BD, Baumann MH, Huestis MA.

J Chromatogr A. 2016 Jun 17;1451:97-106. doi: 10.1016/j.chroma.2016.05.020. Epub 2016 May 6.

16.

Simultaneous quantification of buprenorphine, naloxone and phase I and II metabolites in plasma and breastmilk by liquid chromatography-tandem mass spectrometry.

Swortwood MJ, Scheidweiler KB, Barnes AJ, Jansson LM, Huestis MA.

J Chromatogr A. 2016 May 13;1446:70-7. doi: 10.1016/j.chroma.2016.03.076. Epub 2016 Mar 31.

PMID:
27083254
17.

Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry.

Andersson M, Diao X, Wohlfarth A, Scheidweiler KB, Huestis MA.

Rapid Commun Mass Spectrom. 2016 Apr 30;30(8):1067-78. doi: 10.1002/rcm.7538.

PMID:
27003044
18.

In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22.

Diao X, Scheidweiler KB, Wohlfarth A, Pang S, Kronstrand R, Huestis MA.

AAPS J. 2016 Mar;18(2):455-64. doi: 10.1208/s12248-016-9867-4. Epub 2016 Jan 25.

19.

Delayed emergence of methamphetamine's enhanced cardiovascular effects in nonhuman primates during protracted methamphetamine abstinence.

Vaupel DB, Schindler CW, Chefer S, Belcher AM, Ahmet I, Scheidweiler KB, Huestis MA, Stein EA.

Drug Alcohol Depend. 2016 Feb 1;159:181-9. doi: 10.1016/j.drugalcdep.2015.12.008. Epub 2015 Dec 24.

20.

High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes.

Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA.

Clin Chem. 2016 Jan;62(1):157-69. doi: 10.1373/clinchem.2015.243535. Epub 2015 Oct 1.

21.

Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation.

Wohlfarth A, Scheidweiler KB, Pang S, Zhu M, Castaneto M, Kronstrand R, Huestis MA.

Drug Test Anal. 2016 Aug;8(8):779-91. doi: 10.1002/dta.1856. Epub 2015 Sep 1.

22.

Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA.

Wohlfarth A, Castaneto MS, Zhu M, Pang S, Scheidweiler KB, Kronstrand R, Huestis MA.

AAPS J. 2015 May;17(3):660-77. doi: 10.1208/s12248-015-9721-0. Epub 2015 Feb 28.

23.

Quantification of six cannabinoids and metabolites in oral fluid by liquid chromatography-tandem mass spectrometry.

Desrosiers NA, Scheidweiler KB, Huestis MA.

Drug Test Anal. 2015 Aug;7(8):684-94. doi: 10.1002/dta.1753. Epub 2014 Nov 26.

PMID:
25428610
24.

Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens.

Wohlfarth A, Scheidweiler KB, Castaneto M, Gandhi AS, Desrosiers NA, Klette KL, Martin TM, Huestis MA.

Clin Chem Lab Med. 2015 Feb;53(3):423-34. doi: 10.1515/cclm-2014-0612.

PMID:
25263309
25.

Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens.

Castaneto MS, Scheidweiler KB, Gandhi A, Wohlfarth A, Klette KL, Martin TM, Huestis MA.

Drug Test Anal. 2015 Jun;7(6):483-93. doi: 10.1002/dta.1709. Epub 2014 Sep 17.

26.

Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry.

Scheidweiler KB, Jarvis MJ, Huestis MA.

Anal Bioanal Chem. 2015 Jan;407(3):883-97. doi: 10.1007/s00216-014-8118-8. Epub 2014 Sep 16.

PMID:
25224637
27.

Metabolite profiling of RCS-4, a novel synthetic cannabinoid designer drug, using human hepatocyte metabolism and TOF-MS.

Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Huestis MA.

Bioanalysis. 2014 Jun;6(11):1471-85. doi: 10.4155/bio.14.13.

28.

Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS.

Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Huestis MA.

Bioanalysis. 2014 May;6(9):1187-200. doi: 10.4155/bio.14.1.

30.

Quantification of 11-nor-9-carboxy-δ9-tetrahydrocannabinol in human oral fluid by gas chromatography-tandem mass spectrometry.

Barnes AJ, Scheidweiler KB, Huestis MA.

Ther Drug Monit. 2014 Apr;36(2):225-33. doi: 10.1097/01.ftd.0000443071.30662.01.

31.

Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis.

Desrosiers NA, Himes SK, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA.

Clin Chem. 2014 Apr;60(4):631-43. doi: 10.1373/clinchem.2013.216507. Epub 2014 Feb 21.

32.

Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry.

Wohlfarth A, Gandhi AS, Pang S, Zhu M, Scheidweiler KB, Huestis MA.

Anal Bioanal Chem. 2014 Feb;406(6):1763-80. doi: 10.1007/s00216-014-7668-0. Epub 2014 Feb 12.

PMID:
24518903
33.
34.

Validation of a novel method to identify in utero ethanol exposure: simultaneous meconium extraction of fatty acid ethyl esters, ethyl glucuronide, and ethyl sulfate followed by LC-MS/MS quantification.

Himes SK, Concheiro M, Scheidweiler KB, Huestis MA.

Anal Bioanal Chem. 2014 Mar;406(7):1945-55. doi: 10.1007/s00216-013-7600-z. Epub 2014 Jan 10.

35.

In vitro stability of free and glucuronidated cannabinoids in urine following controlled smoked cannabis.

Desrosiers NA, Lee D, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA.

Anal Bioanal Chem. 2014 Jan;406(3):785-92. doi: 10.1007/s00216-013-7524-7. Epub 2013 Dec 1.

36.

Identifying methamphetamine exposure in children.

Castaneto MS, Barnes AJ, Scheidweiler KB, Schaffer M, Rogers KK, Stewart D, Huestis MA.

Ther Drug Monit. 2013 Dec;35(6):823-30. doi: 10.1097/FTD.0b013e31829685b2.

37.

3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration.

Hartman RL, Desrosiers NA, Barnes AJ, Yun K, Scheidweiler KB, Kolbrich-Spargo EA, Gorelick DA, Goodwin RS, Huestis MA.

Anal Bioanal Chem. 2014 Jan;406(2):587-99. doi: 10.1007/s00216-013-7468-y. Epub 2013 Nov 15.

38.

Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers?

Desrosiers NA, Lee D, Concheiro-Guisan M, Scheidweiler KB, Gorelick DA, Huestis MA.

Clin Chem. 2014 Feb;60(2):361-72. doi: 10.1373/clinchem.2013.214106. Epub 2013 Nov 1.

39.

Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat.

Concheiro M, Baumann MH, Scheidweiler KB, Rothman RB, Marrone GF, Huestis MA.

Drug Metab Dispos. 2014 Jan;42(1):119-25. doi: 10.1124/dmd.113.053678. Epub 2013 Oct 18.

40.

Cannabinoids in exhaled breath following controlled administration of smoked cannabis.

Himes SK, Scheidweiler KB, Beck O, Gorelick DA, Desrosiers NA, Huestis MA.

Clin Chem. 2013 Dec;59(12):1780-9. doi: 10.1373/clinchem.2013.207407. Epub 2013 Sep 17.

41.

First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry.

Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Liu HF, Huestis MA.

Clin Chem. 2013 Nov;59(11):1638-48. doi: 10.1373/clinchem.2013.209965. Epub 2013 Sep 6.

42.

First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry.

Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Liu HF, Huestis MA.

AAPS J. 2013 Oct;15(4):1091-8. doi: 10.1208/s12248-013-9516-0. Epub 2013 Aug 3.

43.

11-Nor-9-carboxy-∆9-tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry.

Scheidweiler KB, Himes SK, Chen X, Liu HF, Huestis MA.

Anal Bioanal Chem. 2013 Jul;405(18):6019-27. doi: 10.1007/s00216-013-7027-6. Epub 2013 May 17.

44.

In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis.

Scheidweiler KB, Schwope DM, Karschner EL, Desrosiers NA, Gorelick DA, Huestis MA.

Clin Chem. 2013 Jul;59(7):1108-17. doi: 10.1373/clinchem.2012.201467. Epub 2013 Mar 21.

45.

Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration.

Desrosiers NA, Barnes AJ, Hartman RL, Scheidweiler KB, Kolbrich-Spargo EA, Gorelick DA, Goodwin RS, Huestis MA.

Anal Bioanal Chem. 2013 May;405(12):4067-76. doi: 10.1007/s00216-013-6848-7. Epub 2013 Mar 8.

46.

Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search.

Wohlfarth A, Scheidweiler KB, Chen X, Liu HF, Huestis MA.

Anal Chem. 2013 Apr 2;85(7):3730-8. doi: 10.1021/ac3037365. Epub 2013 Mar 18.

47.

Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws.

Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, Huestis MA.

Clin Chem. 2013 Mar;59(3):519-26. doi: 10.1373/clinchem.2012.195503.

48.

Development and validation of the first liquid chromatography-tandem mass spectrometry assay for simultaneous quantification of multiple antiretrovirals in meconium.

Himes SK, Scheidweiler KB, Tassiopoulos K, Kacanek D, Hazra R, Rich K, Huestis MA; Pediatric HIV/AIDS Cohort Study.

Anal Chem. 2013 Feb 5;85(3):1896-904. doi: 10.1021/ac303188j. Epub 2013 Jan 14.

49.

Prenatal tobacco exposure, biomarkers for tobacco in meconium, and neonatal growth outcomes.

Himes SK, Stroud LR, Scheidweiler KB, Niaura RS, Huestis MA.

J Pediatr. 2013 May;162(5):970-5. doi: 10.1016/j.jpeds.2012.10.045. Epub 2012 Dec 1.

50.

Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry.

Scheidweiler KB, Desrosiers NA, Huestis MA.

Clin Chim Acta. 2012 Nov 20;413(23-24):1839-47. doi: 10.1016/j.cca.2012.06.034. Epub 2012 Jul 6.

Supplemental Content

Loading ...
Support Center